Buscar
Aurinia Pharmaceuticals Inc
AUPHAñadir a la lista de seguimiento
14.880USD
-0.120-0.80%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.91BCap. mercado
6.68P/E TTM
Más Datos de Aurinia Pharmaceuticals Inc Compañía
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Información de Aurinia Pharmaceuticals Inc
Símbolo de cotizaciónAUPH
Nombre de la empresaAurinia Pharmaceuticals Inc
Fecha de salida a bolsaJul 16, 2001
Director ejecutivoGreenleaf (Peter S)
Número de empleados130
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
Dirección#140, 14315 - 118 Avenue
CiudadEDMONTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalT5L 4S6
Teléfono12507442487
Sitio Webhttps://www.auriniapharma.com
Símbolo de cotizaciónAUPH
Fecha de salida a bolsaJul 16, 2001
Director ejecutivoGreenleaf (Peter S)
Ejecutivos de Aurinia Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+31.87%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
389.18K
+29.69%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
28.53K
+59.79%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-21.87%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey A. Bailey
Mr. Jeffrey A. Bailey
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+31.87%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
389.18K
+29.69%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
28.53K
+59.79%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-21.87%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Aurinia Pharmaceuticals Inc?
Los cinco principales accionistas de Aurinia Pharmaceuticals Inc son: Mr. Peter S. Greenleaf
¿Cuántas instituciones poseen acciones de Aurinia Pharmaceuticals Inc (AUPH)?
A fecha de 2026Q1, 483 instituciones poseen acciones de Aurinia Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 74.86M, lo que representa el 58.21% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -419172.00.